血浆磷酸化Tau 217免疫测定法对阿尔茨海默病病理的诊断准确性
该队列研究纳入3个单中心观察性队列共786名参与者,评估新型商用血浆p-tau217免疫测定法检测AD病理的效用。结果显示,该测定法识别Aβ和tau病理的AUC分别为0.92-0.96和0.93-0.97,与脑脊液生物标志物相当,3区间参考可减少约80%的确证性检测。纵向分析中,血浆p-tau217仅在Aβ阳性个体中呈年增长,tau阳性者增幅最高。
要点
- 血浆p-tau217免疫测定法在各队列中识别Aβ病理的AUC为0.92-0.96(95%CI 0.89-0.99),识别tau病理的AUC为0.93-0.97(95%CI 0.84-0.99)。
- 使用3区间参考检测异常Aβ病理可重复,并减少约80%的确证性检测。
- 纵向观察中,血浆p-tau217仅在Aβ阳性个体中呈年增长,tau阳性者增幅最高。
核心结论
- 商用血浆p-tau217免疫测定法能准确识别生物学AD,与脑脊液生物标志物结果相当,且各队列间截断值可重复。
- 该测定法可检测纵向变化,包括临床前阶段的变化。
研究设计与样本
- 研究为队列研究,分析3个单中心观察性队列的数据:TRIAD队列(访视时间2017年10月至2021年8月)的横断面和纵向数据、WRAP队列(访视时间2007年2月至2020年11月)的横断面和纵向数据、SPIN队列(基线访视时间2009年3月至2021年11月)的横断面数据。
- 共纳入786名参与者(平均[SD]年龄66.3[9.7]岁;女性504名[64.1%],男性282名[35.9%])。
- 参与者包括有认知障碍和无认知障碍的个体,根据PET或脑脊液生物标志物按淀粉样蛋白和tau(AT)状态分组。
- 数据于2023年2月至6月进行分析。
主要发现
- 在所有队列中,识别Aβ升高(AUC 0.92-0.96;95%CI 0.89-0.99)和tau病理(AUC 0.93-0.97;95%CI 0.84-0.99)均观察到高准确性。
- 这些准确性与脑脊液生物标志物在确定异常PET信号方面相当。
- 使用3区间参考检测异常Aβ病理可产生可重复的结果,并减少约80%的确证性检测。
- 纵向观察中,血浆p-tau217值仅在Aβ阳性个体中呈年增长,tau阳性者增幅最高。
关键数值与推荐
- 血浆p-tau217识别Aβ升高的AUC为0.92-0.96(95%CI 0.89-0.99),识别tau病理的AUC为0.93-0.97(95%CI 0.84-0.99)。
- 使用3区间参考检测异常Aβ病理可减少约80%的确证性检测。
临床怎么用
- 本研究表明商用血浆p-tau217免疫测定法可准确识别生物学AD,与脑脊液生物标志物结果相当,且截断值可重复。
- 作者指出该测定法可检测纵向变化,包括临床前阶段。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Phosphorylated tau (p-tau) is a specific blood biomarker for Alzheimer disease (AD) pathology, with p-tau217 considered to have the most utility. However, availability of p-tau217 tests for research and clinical use has been limited. Expanding access to this highly accurate AD biomarker is crucial for wider evaluation and implementation of AD blood tests. OBJECTIVE: To determine the utility of a novel and commercially available immunoassay for plasma p-tau217 to detect AD pathology and evaluate reference ranges for abnormal amyloid β (Aβ) and longitudinal change across 3 selected cohorts. DESIGN, SETTING, AND PARTICIPANTS: This cohort study examined data from 3 single-center observational cohorts: cross-sectional and longitudinal data from the Translational Biomarkers in Aging and Dementia (TRIAD) cohort (visits October 2017-August 2021) and Wisconsin Registry for Alzheimer's Prevention (WRAP) cohort (visits February 2007-November 2020) and cross-sectional data from the Sant Pau Initiative on Neurodegeneration (SPIN) cohort (baseline visits March 2009-November 2021). Participants included individuals with and without cognitive impairment grouped by amyloid and tau (AT) status using PET or CSF biomarkers. Data were analyzed from February to June 2023. EXPOSURES: Magnetic resonance imaging, Aβ positron emission tomography (PET), tau PET, cerebrospinal fluid (CSF) biomarkers (Aβ42/40 and p-tau immunoassays), and plasma p-tau217 (ALZpath pTau217 assay). MAIN OUTCOMES AND MEASURES: Accuracy of plasma p-tau217 in detecting abnormal amyloid and tau pathology, longitudinal p-tau217 change according to baseline pathology status. RESULTS: The study included 786 participants (mean [SD] age, 66.3 [9.7] years; 504 females [64.1%] and 282 males [35.9%]). High accuracy was observed in identifying elevated Aβ (area under the curve [AUC], 0.92-0.96; 95% CI, 0.89-0.99) and tau pathology (AUC, 0.93-0.97; 95% CI, 0.84-0.99) across all cohorts. These accuracies were comparable with CSF biomarkers in determining abnormal PET signal. The detection of abnormal Aβ pathology using a 3-range reference yielded reproducible results and reduced confirmatory testing by approximately 80%. Longitudinally, plasma p-tau217 values showed an annual increase only in Aβ-positive individuals, with the highest increase observed in those with tau positivity. CONCLUSIONS AND RELEVANCE: This study found that a commercially available plasma p-tau217 immunoassay accurately identified biological AD, comparable with results using CSF biomarkers, with reproducible cut-offs across cohorts. It detected longitudinal changes, including at the preclinical stage.
引用
- Ashton NJ, Brum WS, Di Molfetta G, et al. Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology. JAMA Neurol. 2024. PMID: 38252443. doi:10.1001/jamaneurol.2023.5319
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。